MPM BioVentures 2014, L.P. has demonstrated a clear selling bias in recent months, with no recorded purchases across its 28 reported transactions. The firm has exclusively divested shares of Werewolf Therapeutics, Inc. (HOWL), executing 25 sales between October 30 and December 4, 2025, totaling approximately $2.22 million. The disposals occurred in a steady cadence, with daily sales ranging from $20,074 on November 28 to $171,395 on November 4, suggesting a structured exit strategy rather than reactionary trading.
The largest single sale took place on November 4, when MPM offloaded $171,395 worth of HOWL shares, followed by a $145,976 transaction on October 31. While the pace of selling remained consistent through November and early December, the transaction sizes tapered slightly toward the end of the period, with December sales averaging around $60,000 per day. The concentrated activity in HOWL—the only stock traded—indicates a focused reduction in MPM’s position, though the firm’s remaining stake, if any, is not disclosed in the filings. The absence of any buying activity during this period reinforces a singular direction in the firm’s recent trading behavior.
AI-assisted summary